Panida Panitsillapakit

Dr. Panida Panitsillapakit


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
NKNarudee Kashemsant
Narudee Kashemsant
PPPanida Panitsillapakit
Panida Panitsillapakit
MVMonchanok Vijarnsorn
Monchanok Vijarnsorn
CLChalermpol Lekcharoensuk
Chalermpol Lekcharoensuk
SYSarawut Yangtara
Sarawut Yangtara
BLB. Duncan Lascelles
B. Duncan Lascelles
Canine hip osteoarthritis (OA) is a common musculoskeletal disorder requiring mul-tidimensional assessment. This randomized, double-blind, placebo-controlled trial evaluated 4-week treatment with meloxicam, two marine-based fatty acid com-pounds, combination treatment, or placebo in 203 client-owned dogs with naturally occurring hip OA. The principal outcome was peak vertical force (PVF) of the index hindlimb measured by force-plate gait analysis. Secondary outcomes included PVF responder status, orthopedic assessment score (OAS), Liverpool Osteoarthritis in Dogs (LOAD), Canine Brief Pain Inventory (CBPI), adverse events, and laboratory safety variables. Baseline-adjusted mean PVF did not differ significantly among treatment groups, although within-group PVF increased in the meloxicam group be-tween weeks 2 and 4. Using a predefined >5% of body weight PVF responder thresh-old, meloxicam-treated dogs were more likely than placebo-treated dogs to respond at week 4 (relative risk = 4.000; 95% confidence interval, 1.223 to 13.079; p = 0.022). Combination treatment was associated with improvements in LOAD and CBPI pain interference, PCSO-524 showed within-group improvement mainly in LOAD score, and EAB-277 showed within-group improvement in CBPI pain interference. OAS did not change significantly, and no consistent group-level laboratory safety concern was detected. These findings support multidimensional assessment of short-term treat-ment response in canine hip OA.

30 October 2026 in Animals
Verified
Journal Article
Open access
PDF file
NKNarudee Kashemsant
Narudee Kashemsant
PPPanida Panitsillapakit
Panida Panitsillapakit
MVMonchanok Vijarnsorn
Monchanok Vijarnsorn
CLChalermpol Lekcharoensuk
Chalermpol Lekcharoensuk
SYSarawut Yangtara
Sarawut Yangtara
BLB. Duncan Lascelles
B. Duncan Lascelles
Canine hip osteoarthritis (OA) requires multidimensional assessment. This randomized, double-blind, placebo-controlled trial evaluated 4-week treatment with meloxicam, PCSO-524, EAB-277, meloxicam plus PCSO-524, or placebo in 203 client-owned dogs with naturally occurring hip OA. The principal outcome was index-hindlimb peak vertical force (PVF) measured by force-plate gait analysis. Secondary outcomes included PVF responder status, orthopedic assessment score (OAS), Liverpool Osteoarthritis in Dogs (LOAD), Canine Brief Pain Inventory (CBPI), and safety assessments. The primary baseline-adjusted mean PVF analysis did not demonstrate treatment superiority among groups. A secondary responder analysis using an analysis-stage >5%BW PVF threshold showed that meloxicam had a nominally higher Week 4 responder probability than placebo (relative risk = 4.000; 95% confidence interval, 1.223 to 13.079; p = 0.022), interpreted as supportive rather than confirmatory. Within-group score reductions were observed in LOAD and CBPI pain interference for the combination group, LOAD for PCSO-524, and CBPI pain interference for EAB-277. OAS did not change significantly within any group. Between-group differences in LOAD and CBPI changes were not significant. No consistent group-level laboratory safety concern was detected. These findings support multidimensional assessment while emphasizing that secondary results do not establish treatment superiority.